Overall, the therapeutic potential of inhibitors that block the activity of S1P-metabolizing enzymes and S1PR for the treatment of viral diseases and immunologic disorders necessitates a deeper understanding of viral interaction with the sphingolipid network. This evidence concerns the gene MBTPS1 and viral infectious disease.